Medical Countermeasures Against Henipaviruses: a Review and Public Health Perspective

Overview

Journal Lancet Infect Dis

Specialty Infectious Diseases

Date 2021 Nov 4

PMID 34735799

Citations 12

Authors

Raul Gomez Roman

Nadia Tornieporth

Neil George Cherian

Amy C Shurtleff

Maina LAzou Jackson

Debra Yeskey

Adam Hacker

Eric Mungai

Tung Thanh Le

Affiliations

Soon will be listed here.

Abstract

Henipaviruses, including Nipah virus, are regarded as pathogens of notable epidemic potential because of their high pathogenicity and the paucity of specific medical countermeasures to control infections in humans. We review the evidence of medical countermeasures against henipaviruses and project their cost in a post-COVID-19 era. Given the sporadic and unpredictable nature of henipavirus outbreaks, innovative strategies will be needed to circumvent the infeasibility of traditional phase 3 clinical trial regulatory pathways. Stronger partnerships with scientific institutions and regulatory authorities in low-income and middle-income countries can inform coordination of appropriate investments and development of strategies and normative guidelines for the deployment and equitable use of multiple medical countermeasures. Accessible measures should include global, regional, and endemic in-country stockpiles of reasonably priced small molecules, monoclonal antibodies, and vaccines as part of a combined collection of products that could help to control henipavirus outbreaks and prevent future pandemics.

Citing Articles

Cedar virus biology and its applications as a surrogate for highly pathogenic henipaviruses.

Sabir A, Rong L, Broder C, Amaya M Cell Insight. 2025; 3(4):100181.

PMID: 39967899 PMC: 11832809. DOI: 10.1016/j.cellin.2024.100181.

Henipaviruses: epidemiology, ecology, disease, and the development of vaccines and therapeutics.

Spengler J, Lo M, Welch S, Spiropoulou C Clin Microbiol Rev. 2024; 38(1):e0012823.

PMID: 39714175 PMC: 11905374. DOI: 10.1128/cmr.00128-23.

Establishing an immune correlate of protection for Nipah virus in nonhuman primates.

Leyva-Grado V, Promeneur D, Agans K, Lazaro G, Borisevich V, Deer D NPJ Vaccines. 2024; 9(1):244.

PMID: 39702562 PMC: 11659318. DOI: 10.1038/s41541-024-01036-2.

Structure of the Nipah virus polymerase phosphoprotein complex.

Yang G, Wang D, Liu B Nat Commun. 2024; 15(1):8673.

PMID: 39375338 PMC: 11458586. DOI: 10.1038/s41467-024-52701-y.

Ferritin nanoparticle-based Nipah virus glycoprotein vaccines elicit potent protective immune responses in mice and hamsters.

Chen S, Zhang X, Yao Y, Wang S, Li K, Zhang B Virol Sin. 2024; 39(6):909-916.

PMID: 39293542 PMC: 11738763. DOI: 10.1016/j.virs.2024.09.005.

References

Dang H, Chan Y, Park Y, Snijder J, Da Silva S, Vu B . An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections. Nat Struct Mol Biol. 2019; 26(10):980-987. PMC: 6858553. DOI: 10.1038/s41594-019-0308-9. View

Prescott J, DeBuysscher B, Feldmann F, Gardner D, Haddock E, Martellaro C . Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease. Vaccine. 2015; 33(24):2823-9. PMC: 4433813. DOI: 10.1016/j.vaccine.2015.03.089. View

Pedrera M, Macchi F, McLean R, Franceschi V, Thakur N, Russo L . Bovine Herpesvirus-4-Vectored Delivery of Nipah Virus Glycoproteins Enhances T Cell Immunogenicity in Pigs. Vaccines (Basel). 2020; 8(1). PMC: 7157636. DOI: 10.3390/vaccines8010115. View

Pallister J, Middleton D, Crameri G, Yamada M, Klein R, Hancock T . Chloroquine administration does not prevent Nipah virus infection and disease in ferrets. J Virol. 2009; 83(22):11979-82. PMC: 2772715. DOI: 10.1128/JVI.01847-09. View

Cohen M . Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection. N Engl J Med. 2021; 384(3):289-291. PMC: 7844860. DOI: 10.1056/NEJMe2034495. View

Walpita P, Cong Y, Jahrling P, Rojas O, Postnikova E, Yu S . A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model. NPJ Vaccines. 2017; 2:21. PMC: 5627259. DOI: 10.1038/s41541-017-0023-7. View

Nikolay B, Salje H, Hossain M, Khan A, Sazzad H, Rahman M . Transmission of Nipah Virus - 14 Years of Investigations in Bangladesh. N Engl J Med. 2019; 380(19):1804-1814. PMC: 6547369. DOI: 10.1056/NEJMoa1805376. View

Lurie N, Saville M, Hatchett R, Halton J . Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020; 382(21):1969-1973. DOI: 10.1056/NEJMp2005630. View

Wang Y, Park A, Lake M, Pentecost M, Torres B, Yun T . Ubiquitin-regulated nuclear-cytoplasmic trafficking of the Nipah virus matrix protein is important for viral budding. PLoS Pathog. 2010; 6(11):e1001186. PMC: 2978725. DOI: 10.1371/journal.ppat.1001186. View

10.

Mire C, Geisbert J, Agans K, Feng Y, Fenton K, Bossart K . A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge. J Virol. 2014; 88(9):4624-31. PMC: 3993805. DOI: 10.1128/JVI.00005-14. View

11.

Lo M, Amblard F, Flint M, Chatterjee P, Kasthuri M, Li C . Potent in vitro activity of β-D-4'-chloromethyl-2'-deoxy-2'-fluorocytidine against Nipah virus. Antiviral Res. 2020; 175:104712. PMC: 7054849. DOI: 10.1016/j.antiviral.2020.104712. View

12.

Kalodimou G, Veit S, Jany S, Kalinke U, Broder C, Sutter G . A Soluble Version of Nipah Virus Glycoprotein G Delivered by Vaccinia Virus MVA Activates Specific CD8 and CD4 T Cells in Mice. Viruses. 2019; 12(1). PMC: 7019319. DOI: 10.3390/v12010026. View

13.

Vaughan K, Ozaltin A, Mallow M, Moi F, Wilkason C, Stone J . The costs of delivering vaccines in low- and middle-income countries: Findings from a systematic review. Vaccine X. 2019; 2:100034. PMC: 6697256. DOI: 10.1016/j.jvacx.2019.100034. View

14.

Tan C, Goh K, Wong K, Sarji S, Chua K, Chew N . Relapsed and late-onset Nipah encephalitis. Ann Neurol. 2002; 51(6):703-8. DOI: 10.1002/ana.10212. View

15.

Pickering B, Hardham J, Smith G, Weingartl E, Dominowski P, Foss D . Protection against henipaviruses in swine requires both, cell-mediated and humoral immune response. Vaccine. 2016; 34(40):4777-86. PMC: 6161494. DOI: 10.1016/j.vaccine.2016.08.028. View

16.

Schmidt R, Beltzig L, Sawatsky B, Dolnik O, Dietzel E, Krahling V . Generation of therapeutic antisera for emerging viral infections. NPJ Vaccines. 2018; 3:42. PMC: 6173733. DOI: 10.1038/s41541-018-0082-4. View

17.

Pallister J, Middleton D, Wang L, Klein R, Haining J, Robinson R . A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine. 2011; 29(34):5623-30. PMC: 3153950. DOI: 10.1016/j.vaccine.2011.06.015. View

18.

Bossart K, Geisbert T, Feldmann H, Zhu Z, Feldmann F, Geisbert J . A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med. 2011; 3(105):105ra103. PMC: 3313625. DOI: 10.1126/scitranslmed.3002901. View

19.

Hotard A, He B, Nichol S, Spiropoulou C, Lo M . 4'-Azidocytidine (R1479) inhibits henipaviruses and other paramyxoviruses with high potency. Antiviral Res. 2017; 144:147-152. PMC: 5648002. DOI: 10.1016/j.antiviral.2017.06.011. View

20.

Bossart K, Zhu Z, Middleton D, Klippel J, Crameri G, Bingham J . A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog. 2009; 5(10):e1000642. PMC: 2765826. DOI: 10.1371/journal.ppat.1000642. View